Support for Cancer Clinical Trials Program Grant

Overview

Important advances in cancer prevention, treatment and care can be made through clinical trials. Industry-independent cancer clinical trials can play an important role in the cancer research landscape because these trials can address important questions in patient treatment and care that may not be of commercial interest to industry. The primary aim of the Support for Cancer Clinical Trials program is to support Australia’s Multi-site Collaborative Cancer Clinical Trials Groups (CTGs) to develop industry-independent cancer clinical trial protocols to the stage of application for grant funding.   The broader program objectives are to:  • increase the number of cancer clinical trials conducted in Australia • increase participation in clinical trials by people affected by cancer  • increase the number of clinical sites actively participating in cancer clinical trials • increase the involvement of policy makers, clinicians, researchers and consumers in the development of cancer clinical trials  • increase CTG participation in national multi-group or international cancer clinical trials in Australia. In line with Cancer Australia’s priority to reduce disparity in cancer outcomes, the following specific goals are considered additional key priorities towards addressing the broader program objectives ‘increase the participation in clinical trials by people affected by cancer’ and ‘increase the number of clinical sites actively participating in cancer clinical trials’: • increase access to clinical trials for rural/remote Australia through teletrials • increase trial participation among Aboriginal and Torres Strait Islander peoples  • increase trial participation among populations where there is low uptake into clinical trials including people from culturally and linguistically diverse (CALD) backgrounds, older Australians and adolescents and young adults (AYA).